TrialAnnals of oncology : official journal of the European Society for Medical Oncology2016

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

P Saiag et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.